Mirion Technologies, Inc. logo

Mirion Technologies, Inc.

MIR

NYSEIndustrialsIndustrial - Machinery

Previous close

$14.82

−$0.41 · -2.69%

Aug 21, 4:00 PM ET

MIR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

43

Fair Value

Momentum

27

Weakening

Sentiment

69

Bullish

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).

Industry
Industrial - Machinery
Sector
Industrials
Headquarters
US
CEO
Thomas D. Logan
Listed since
Aug 20, 2020
Employees
3,281

Market position

Day range

Current $14.82

52-week range

Current $14.82

Open
$15.40
Previous close
$15.23
Volume
4.06M
1× average
Average volume
4.07M
Average daily volume
Market cap
3.61B USD
Beta
1.06
Market reference 1
50-day average
$16.444
-9.88% below average
200-day average
$20.58
-27.99% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.21B USD
P/E (TTM)
149.7×
P/B (TTM)
1.99×
P/S (TTM)
3.52×
EV / EBITDA
29.15×
Earnings yield
0.53%
Free cash flow yield
1.98%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
48.00%
Operating margin
5.32%
Net margin
2.39%
Return on equity
1.54%
Return on assets
0.80%
Return on invested capital
1.43%

Financial health

Debt / equity
0.68×
Current ratio
2.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends56%21%-15%-50%Gross margin, FY2021: 42.53%Gross margin, FY2022: 44.19%Gross margin, FY2023: 44.51%Gross margin, FY2024: 46.68%Gross margin, FY2025: 47.40%Operating margin, FY2021: -10.28%Operating margin, FY2022: -41.49%Operating margin, FY2023: -2.73%Operating margin, FY2024: 2.88%Operating margin, FY2025: 5.57%Net margin, FY2021: -33.29%Net margin, FY2022: -38.58%Net margin, FY2023: -12.10%Net margin, FY2024: -4.19%Net margin, FY2025: 3.11%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 42.53%. Gross margin FY2022 44.19%. Gross margin FY2023 44.51%. Gross margin FY2024 46.68%. Gross margin FY2025 47.40%. Operating margin FY2021 -10.28%. Operating margin FY2022 -41.49%. Operating margin FY2023 -2.73%. Operating margin FY2024 2.88%. Operating margin FY2025 5.57%. Net margin FY2021 -33.29%. Net margin FY2022 -38.58%. Net margin FY2023 -12.10%. Net margin FY2024 -4.19%. Net margin FY2025 3.11%.

Income trends

Revenue

925.4M USD+7.50%

Operating income

51.5M USD+107.66%

Net income

28.8M USD+64.9M USD
Income trends across reported periods1.05B USD558.44M USD69.16M USD−420.12M USDRevenue, FY2021: 668.3M USDRevenue, FY2022: 717.8M USDRevenue, FY2023: 800.9M USDRevenue, FY2024: 860.8M USDRevenue, FY2025: 925.4M USDOperating income, FY2021: −68.7M USDOperating income, FY2022: −297.8M USDOperating income, FY2023: −21.9M USDOperating income, FY2024: 24.8M USDOperating income, FY2025: 51.5M USDNet income, FY2021: −222.5M USDNet income, FY2022: −276.9M USDNet income, FY2023: −96.9M USDNet income, FY2024: −36.1M USDNet income, FY2025: 28.8M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 668.3M USD. Revenue FY2022 717.8M USD. Revenue FY2023 800.9M USD. Revenue FY2024 860.8M USD. Revenue FY2025 925.4M USD. Operating income FY2021 −68.7M USD. Operating income FY2022 −297.8M USD. Operating income FY2023 −21.9M USD. Operating income FY2024 24.8M USD. Operating income FY2025 51.5M USD. Net income FY2021 −222.5M USD. Net income FY2022 −276.9M USD. Net income FY2023 −96.9M USD. Net income FY2024 −36.1M USD. Net income FY2025 28.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue925.4M USD860.8M USD800.9M USD717.8M USD668.3M USD
Cost of goods sold486.8M USD459M USD444.4M USD400.6M USD384.1M USD
Gross profit438.6M USD401.8M USD356.5M USD317.2M USD284.2M USD
Research and development38.9M USD35M USD31.7M USD30.3M USD36.2M USD
Selling, general, and administrative348.2M USD338.2M USD338.6M USD357.1M USD267.6M USD
Operating expenses387.1M USD377M USD378.4M USD615M USD352.9M USD
Interest income12.1M USD6.6M USD4.8M USD600K USD145.8M USD
Interest expense42.2M USD57.9M USD61.9M USD42.5M USD59M USD
Depreciation and amortization138M USD150.4M USD162.8M USD174.5M USD112.2M USD
Operating income51.5M USD24.8M USD−21.9M USD−297.8M USD−68.7M USD
Net income28.8M USD−36.1M USD−96.9M USD−276.9M USD−222.5M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 2 misses, 3 met estimates
Average EPS surprise
+5.02%
11 comparable reports
Latest EPS result
0.12
Estimate 0.1 · Beat by 16.05%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.210.170.130.09Q1 '25BeatQ2 '25MetQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 0.17, estimate 0.14, surprise +21.43%, Beat. Q2 2025, reported Apr 29, 2025: actual 0.1, estimate 0.1, surprise 0.00%, Met estimate. Q3 2025, reported Jul 31, 2025: actual 0.11, estimate 0.1, surprise +10.00%, Beat. Q4 2025, reported Oct 28, 2025: actual 0.12, estimate 0.11, surprise +9.09%, Beat. Q1 2026, reported Feb 10, 2026: actual 0.15, estimate 0.16, surprise -6.25%, Miss. Q2 2026, reported Apr 28, 2026: actual 0.1, estimate 0.1, surprise 0.00%, Met estimate. Q3 2026, reported Jul 28, 2026: actual 0.12, estimate 0.103, surprise +16.05%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates292.42M258.53M224.64M190.75MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 254.3M USD, estimate 245.02M USD, surprise +3.79%, Beat. Q2 2025, reported Apr 29, 2025: actual 202M USD, estimate 219.12M USD, surprise -7.81%, Miss. Q3 2025, reported Jul 31, 2025: actual 222.9M USD, estimate 222.53M USD, surprise +0.17%, Beat. Q4 2025, reported Oct 28, 2025: actual 223.1M USD, estimate 281.17M USD, surprise -20.65%, Miss. Q1 2026, reported Feb 10, 2026: actual 277.4M USD, estimate 280.33M USD, surprise -1.05%, Miss. Q2 2026, reported Apr 28, 2026: actual 257.6M USD, estimate 244.78M USD, surprise +5.24%, Beat. Q3 2026, reported Jul 28, 2026: actual 266.8M USD, estimate 269.32M USD, surprise -0.93%, Miss. Q4 2026, reported Oct 27, 2026: actual —, estimate 274.28M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

9 ratings
Strong buy00%
Buy889%
Hold111%
Sell00%
Strong sell00%

Recent analyst actions

8 institutions
Evercore ISI GroupmaintainOutperform
Northland Capital MarketsmaintainOutperform

MIR news

MIR peers

ETFs holding MIR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MIR

research.disclaimer